Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 4/20 | 0.36 |
| ▸ | PDE4A | P27815 | 5/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522891 | 0.82 | TSHR (0.48) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3524552 | 0.70 | MAOA (0.45) | MAPTMEN1KMT2A | |
| SCHEMBL11554378 | 0.69 | LMNA (0.36) | ADORA2BADORA2ARECQLTSHRMAPT | |
| SCHEMBL13760637 | 0.68 | TNF (0.32) | TNF | |
| SCHEMBL3521483 | 0.68 | TNF (0.35) | TNF | |
| SCHEMBL23974960 | 0.66 | CYP1A2 (0.54) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3786380 | 0.66 | ADORA2A (0.37) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3828161 | 0.65 | TSHR (0.74) | RECQLTSHRMAPTMEN1KMT2A | |
| SCHEMBL3522099 | 0.65 | PDE1A (0.35) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL318169 | 0.64 | TSHR (0.64) | CYP1A2TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2241567-A1 | BICYCLOAMINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009101917-A1 | BICYCLOAMINE DERIVATIVE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | ADORA2B 970/4885PDE4A 1708/4885PDE4B 1453/4885 |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | ADORA2B 970/4885PDE4A 1708/4885PDE4B 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.